This summer, four new biosimilar drugs became available to U.S. patients and several more are expected to hit the market soon.

Dr. Michael Weinstein interviews Laura D. Wingate, executive vice president, education, support, & advocacy for the Crohn’s & Colitis Foundation about the positive and negative implications of this development for patients.

While increased competition in the market is likely to expand the range of options available, potentially leading to reduced costs for medications, a recent survey conducted by the Crohn’s & Colitis Foundation found that almost 50% of IBD patients feel concerned about switching to biosimilars. Additionally, the insurance industry may limit consumer choices to these medications.

Join Dr. Weinstein and Laura as they discuss the importance of educating patients about the availability of biosimilars and how physicians can advocate for access to these safe and effective options.

Produced by Andrew Sousa and Hayden Margolis for Steadfast Collaborative, LLC

Mixed and mastered by Hayden Margolis

Gastro Broadcast, Episode 48